Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in previously treated metastatic colorectal cancer
NCT02870582Phase 3Completed
- Sponsor
- Zelgen
- Start
- Dec 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donafenib in metastatic colorectal cancer (mCRC), sponsored by Zelgen. Started Dec 2016; status: completed.
02
Drugs
donafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02870582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870582.